MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock from...
$187,872K
Net cash provided by
financing activities
$187,872K
(885.58%↑ Y/Y)
Net change in cash
and cash...
$8,317K
(136.34%↑ Y/Y)
Canceled cashflow
$179,555K
Proceeds from maturities
of investments
$36,312K
(-67.08%↓ Y/Y)
Stock-based compensation
$12,440K
(-40.36%↓ Y/Y)
Depreciation and
amortization
$2,645K
(-57.37%↓ Y/Y)
Accrued and other
current liabilities
$2,280K
(165.37%↑ Y/Y)
Non-cash rent expense
$1,080K
(-52.57%↓ Y/Y)
Accounts payable
$1,031K
(236.02%↑ Y/Y)
Other long-term
liabilities
$356K
(-20.36%↓ Y/Y)
Net cash provided by
(used in) investing...
-$147,559K
(-395.05%↓ Y/Y)
Net cash used in
operating activities
-$31,996K
(65.21%↑ Y/Y)
Canceled cashflow
$36,312K
Canceled cashflow
$19,832K
Collaboration revenue -
related party
$4,640K
Other income
(expenses), net
$4,243K
Purchase of investments
$183,721K
(205.46%↑ Y/Y)
Net loss
-$42,677K
(61.44%↑ Y/Y)
Purchases of property and
equipment
$150K
(4.90%↑ Y/Y)
Canceled cashflow
$8,883K
Non-cash collaboration
revenue - related party
$4,640K
Operating lease
liabilities
-$2,043K
(45.65%↑ Y/Y)
Net
amortization/accretion on investment...
$1,313K
(-46.99%↓ Y/Y)
Prepaid expenses and
other current assets
$989K
(179.63%↑ Y/Y)
Other long-term
assets
$166K
(-88.96%↓ Y/Y)
Total operating
expenses
$51,560K
Back
Back
Cash Flow
Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO)
source: myfinsight.com